Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy

Published:2018-12-04 Issue:2 Volume:266 Page:306-315
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Chalmer Thor Ameri, ,Kalincik Tomas,Laursen Bjarne,Sorensen Per Soelberg,Magyari Melinda

Funder

Scleroseforeningen

Foundation for Research in Neurology

Gangstedfonden

Direktør Ejnar Jonasson Kaldet Johnsen og Hustrus Mindelegat

Publisher

Springer Science and Business Media LLC

Subject

Clinical Neurology,Neurology

Link

http://link.springer.com/article/10.1007/s00415-018-9126-y/fulltext.html

Reference32 articles.

1. Sorensen PS, Blinkenberg M (2016) The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord 9:44–52

2. Sorensen PS (2014) New management algorithms in multiple sclerosis. Curr Opin Neurol 27:246–259

3. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43:655–661

4. Johnson KP, Brooks BR, Cohen JA (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45:1268–1276

5. Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285–294

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Highly Effective Therapy Versus Escalation Approaches in Early Multiple Sclerosis;Neurologic Clinics;2024-02

2. Influence of physicians’ risk perception on switching treatments between high- efficacy and non–high-efficacy disease‑modifying therapies in multiple sclerosis;Multiple Sclerosis and Related Disorders;2023-08

3. Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab;Neurology and Therapy;2023-07-17

4. Iranian specialists’ approach to treatment escalation in multiple sclerosis patients with cognitive impairment;Current Journal of Neurology;2023-05-03

5. Monitoring response to disease-modifying treatment in multiple sclerosis;Neurology Perspectives;2023-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3